Brand Name: Valsartil 40
Manufacturer:Â Incepta Pharmaceuticals Ltd.
Indications
Valsartan is indicated:
For hypertension
To reduce hospitalizations in patients with congestive heart failure
To reduce death in patients who developed congestive heart failure after myocardial infarction
Dosage & Administration
Hypertension:
The usual dose of Valsartan is 80 to 160 mg once daily. The maximum dose is 320 mg daily. Maximum blood pressure reduction occurs within 4 weeks.
Heart failure:
The usual dose is 40 mg twice daily and may be increased to 80-160 mg twice daily.
Post-Myocardial Infarction:
The initial dose after myocardial infarction is 20 mg twice daily. The dose should be increased with a target of 160 mg daily if tolerated without side effects.
Administration of Valsartan with food decreases the absorption of Valsartan by about 40 %, so it should be taken on an empty stomach. No initial dosage adjustment is required for elderly patients with mild to moderate renal and hepatic insufficiency.
Pediatric use: Safety and effectiveness in pediatric patients have not been established.
Geriatric use: No overall difference in the efficacy or safety without some exception.
Side Effects
Valsartan is generally well tolerated and side effects are rare. The most common side effects include headache, dizziness, fatigue, abdominal pain, cough, diarrhea and nausea. Patient may also experience hyperkalemia, impotency, reduced renal function, allergic reactions, dyspnea, constipation, back pain, muscle cramps, rash, anxiety, insomnia and vertigo. Hypotension may also occur if patient have been taking diuretics along with Valsartan.
Precautions
Impaired Hepatic Function: As the majority of Valsartan is eliminated in the bile, care should be exercised in patients with mild to moderate hepatic impairment including biliary obstructive disorder.
Impaired Renal Function: Dosage reduction or discontinuation may be required with patients having pre-existing renal impairment.
Heart Failure and Myocardial Infarction: Caution should be exercised when initiating therapy in patients with heart failure and post-myocardial infarction patients.
Reviews
There are no reviews yet.